Menu

Image of the Day: Teeny Tiny Delivery Balls

Scientists designed autonomous nanovesicles capable of following glucose concentration gradients, even through the blood brain barrier in rats.

Aug 3, 2017
The Scientist Staff

Fluorescently labeled polymersomes sprinkled throughout a petri dish follow a glucose gradient indicated by the green dot. The glow demonstrates an increase in polymersome concentration.JOSEPH ET AL., SCI ADV, 3:E1700362, 2017. Miniscule polymersomes, dubbed “nanoswimmers,” are drug delivery systems designed to use glucose gradients to self-navigate. This ability coupled with other unique aspects of their design allowed for “an increase of almost fourfold in the amount of polymersomes gaining access to the brain parenchyma of rats” versus other types of polymersomes that don’t rely on glucose homing, write the authors in their report.

See A. Joseph et al., “Chemotactic synthetic vesicles: Design and applications in blood-brain barrier crossing,” Science Advances, 3:e1700362, 2017.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.